ROGAINE Rx-TO-OTC SWITCH STUMBLES ON ISSUE OF BALDNESS MISDIAGNOSIS
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE Rx-TO-OTC SWITCH STUMBLES ON ISSUE OF BALDNESS MISDIAGNOSIS resulting in a 10-4 vote against recommending the Rx- to-OTC switch of topical minoxidil 2% at a July 27 meeting of the Nonprescription Drugs Advisory Committee. Before voting against the switch, the committee, which included members of FDA's Dermatologic Drugs and Cardiovascular and Renal Drugs Advisory Committees, voted 8-0 with two abstentions that consumers could not accurately determine that their hair loss is attributable to androgenetic alopecia.